Company: INGN
Filing Date: 2025-03-27
Form Type: DEF 14A
Source: 0000950170-25-045737
Chunk: 96

Company: Inogen Inc
Filing Date: 2025-03-27
Form: DEF 14A
Chunk 96
---
 | $                                                         |   410,474 |     | $                                                             |  (72,875 | ) |     | $                                                  | —      |   |     | $                                                           |       (6 | ) |

*Presented on an averaged basis.

Relationship Between Compensation Actually Paid (CAP) and TSR, Net Loss, and Revenue

The graphs below show the relationship (i) between CAP and the Company’s TSR and between the Company’s TSR and our peer group’s TSR, (ii) between CAP and the Company’s net loss, and (iii) between CAP and revenue.

<div align='center'>-64-</div>

Tabular List of Financial Performance Measures

The following lists the financial performance measures that we believe represents the most important financial performance measures used to link compensation actually paid to our NEOs for 2024 to Company performance:

| Financial List of Performance Measures |
| Revenue                                |
| Adjusted EBITDA                        |
| Total Shareholder Return               |

<div align='center'>-65-</div>

EquityCompensation Plan Information

The following table provides information as of December 31, 2024 with respect to shares of our common stock that may be issued under our existing equity compensation plans.

| Plan category                                                 |     | (a)  Number of      
 securities to       
 be issued           
 upon exercise       
 of outstanding      
 options,            
 warrants and rights |   |     | (b)  Weighted  
 average        
 exercise price 
 of outstanding 
 options,       
 warrants and   
 rights (1)     |   |     | (c)  Number of           
 securities remaining     
 available for future     
 issuance under equity    
 compensation plans       
 (excluding securities    
 reflected in column (a)) |           |
|:--------------------------------------------------------------|:----|:--------------------|:--|:----|:---------------|:--|:----|:-------------------------|----------:|
| Equity compensation plans approved by security holders (2)(3) |     |                     | — |     | $              | — |     |                          | 2,978,434 |
| Equity compensation plans not approved by security holders    |     |                     | — |     |                | — |     |                          |         — |
| Total                                                         |     |                     | — |     | $              | — |     |                          | 2,978,434 |

The weighted average exercise price is calculated based solely on outstanding stock options.

Includes the following plans: 2014 Plan, 2023 Plan and 2014 Employee